Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 2/20 | 0.64 |
| ▸ | TOP2A | P11388 | 2/20 | 0.64 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.62 |
| ▸ | RAB9A | P51151 | 6/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.57 |
| ▸ | NPC1 | O15118 | 5/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | LCK | P06239 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3497474 | 0.80 | TTBK1 (0.47) | BRAFTOP2AMKNK1RAB9ASMN1; SMN2 | |
| SCHEMBL4922091 | 0.76 | RAB9A (0.63) | BRAFTOP2AMKNK1RAB9ASMN1; SMN2 | |
| SCHEMBL4921690 | 0.76 | MKNK1 (0.73) | BRAFTOP2AMKNK1RAB9ASMN1; SMN2 | |
| SCHEMBL29475418 | 0.75 | BRAF (0.72) | BRAFRAB9ASMN1; SMN2NPC1HSD17B10 | |
| SCHEMBL536913 | 0.75 | BRAF (0.72) | BRAFRAB9ASMN1; SMN2NPC1HSD17B10 | |
| SCHEMBL4921756 | 0.73 | PRMT1 (0.70) | BRAFTOP2AMKNK1SMN1; SMN2HSD17B10 | |
| SCHEMBL5241436 | 0.73 | TSHR (0.54) | BRAFMKNK1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL4926098 | 0.73 | MKNK1 (0.73) | BRAFTOP2AMKNK1RAB9ASMN1; SMN2 | |
| SCHEMBL4924939 | 0.72 | MKNK1 (0.59) | BRAFTOP2AMKNK1RAB9ASMN1; SMN2 | |
| SCHEMBL1060507 | 0.72 | MKNK1 (0.72) | BRAFTOP2AMKNK1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137566-A1 | Compounds and Methods Used to Treat Infectious Diseases | CYTOKINE PHARMASCIENCES, INC (US) | 2010-06-03 | — | — | US | disclosed |
| US-20060014760-A1 | Compounds and methods of use to treat infectious diseases | BUKRINSKY MICHAEL I | 2006-01-19 | — | — | US | disclosed |
| US-6906076-B2 | Compounds and methods of use to treat infectious diseases | CYTOKINE PHARMASCIENCES, INC. (US) | 2005-06-14 | — | — | US | disclosed |
| US-20040053815-A1 | Compounds and methods of use to treat infectious diseases | FERRING BV (NL) | 2004-03-18 | — | — | US | disclosed |
| EP-0865434-B1 | COMPOUNDS AND THEIR USE TO TREAT INFECTIOUS DISEASES | PICOWER INST MED RES (US) | 2003-12-17 | — | — | EP | disclosed |
| US-6649797-B2 | Contacting protein with a compound that is capable of stable reversible binding with basic amino acid residues of nuclear localization signal of protein for inactivating a nuclear localization signal of a protein | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH | 2003-11-18 | — | — | US | disclosed |
| US-20020077271-A1 | Compounds and methods of use to treat infectious diseases | FERRING BV (NL) | 2002-06-20 | — | — | US | disclosed |
| US-6297253-B1 | INACTIVATING A NUCLEAR LOCALIZATION SIGNAL OF A PROTEIN COMPRISING CONTACTING THE PROTEIN WITH AN ARYL CARBONYL COMPOUND THAT FORMS STABLE REVERSIBLE COVALENT INTERACTIONS WITH NEIGHBORING BASIC AMINO ACID RESIDUES | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH | 2001-10-02 | — | — | US | disclosed |
| US-5840893-A | TREATING MALARIA, HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1998-11-24 | — | — | US | disclosed |
| WO-1998016515-A1 | COMPOUNDS AND METHODS TO TREAT INFECTIOUS DISEASES | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1998-04-23 | — | — | WO | disclosed |
| US-5733932-A | VIRICIDES MARKING AND BLOCKING SPECIFIC VIRAL PROTEINS | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1998-03-31 | — | — | US | disclosed |
| US-5703086-A | TREATMENT OF HIV INFECTIONS | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1997-12-30 | — | — | US | disclosed |
| US-5620983-A | BLOCKING MOVEMENT OF VIRAL GENOME PARTICLES THROUGH NUCLEAR MEMBRANE IN TERMINALLY DIFFERENTIATED CELLS TO PREVENT VIRAL INFECTIONS | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1997-04-15 | — | — | US | disclosed |
| US-5574040-A | DIALKANOYLPHENYLPYRIMIDINE DERIVATIVES | PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1996-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014760-A1 | Compounds and methods of use to treat infectious diseases | KPNA1, PHAX, NFATC1 | BRAF 4006/4885TOP2A 2683/4885MKNK1 2094/4885 |
| US-20100137566-A1 | Compounds and Methods Used to Treat Infectious Diseases | KPNA1, NFATC1, MAVS | BRAF 3936/4885TOP2A 2621/4885MKNK1 2077/4885 |
| US-20020077271-A1 | Compounds and methods of use to treat infectious diseases | KPNA1, PHAX, NFATC1 | BRAF 4006/4885TOP2A 2683/4885MKNK1 2094/4885 |
| US-20040053815-A1 | Compounds and methods of use to treat infectious diseases | KPNA1, PHAX, NFATC1 | BRAF 4006/4885TOP2A 2683/4885MKNK1 2094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.